In phase III randomized study testing CIMAvax-EGF in advanced NSCLC patients that were previously treated with frontline chemotherapy, results showed that median OS in vaccinated and nonvaccinated patients was 12.43 and 9.43 months. Here, EGF is linked to non-small cell lung carcinoma.